Descending pain modulatory system (DPMS) (DPMS)

The central pain-modulating pathways, primarily the descending pain modulatory system (DPMS), represent a complex network of brain regions and spinal circuits that regulate the transmission of nociceptive information [1.3.1, 1.4.1]. Key anatomical components include the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and the locus coeruleus, which integrate inputs from higher cortical areas like the anterior cingulate cortex and amygdala [1.3.1, 1.4.2]. This system exerts bidirectional control, capable of both inhibiting (antinociception) and facilitating (pronociception) pain signals at the level of the spinal dorsal horn [1.4.2]. Neurotransmitters such as endogenous opioids, serotonin, and norepinephrine play critical roles in mediating these effects [1.3.1, 1.4.3]. Dysregulation of these pathways is a hallmark of chronic pain states, such as fibromyalgia and neuropathic pain, where a shift toward facilitation or a loss of inhibition leads to central sensitization [1.1.2, 1.3.4]. Pharmacological interventions often target these pathways by enhancing inhibitory signaling through opioid receptors or increasing the synaptic availability of norepinephrine and serotonin using antidepressants [1.3.2, 1.3.3]. The system integrates top-down cognitive and emotional influences with bottom-up nociceptive signals to determine the final pain experience [1.4.2]. Therapeutic challenges include the risk of opioid-induced hyperalgesia and the complexity of balancing inhibitory and facilitatory influences [1.4.3].

Other names

Central pain-modulating pathwaysDescending inhibitory pathwaysDescending facilitatory pathwaysEndogenous pain control systemTop-down pain modulation

Drugs targeting these pathways primarily work by enhancing descending inhibitory control or reducing descending facilitation [1.3.1, 1.3.2]. Opioids activate mu-opioid receptors in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) to trigger descending inhibition [1.3.1, 1.4.3]. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) increase the synaptic concentration of norepinephrine and serotonin in the spinal dorsal horn, strengthening endogenous inhibitory circuits [1.3.2, 1.3.3]. Gabapentinoids modulate voltage-gated calcium channels to reduce the release of excitatory neurotransmitters, thereby counteracting central sensitization [1.1.2, 1.3.2].